Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ju, J. F.
Right arrow Articles by Danenberg, P. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ju, J. F.
Right arrow Articles by Danenberg, P. V.

Clinical Cancer Research, Vol 4, Issue 5 1315-1322, Copyright © 1998 by American Association for Cancer Research


ARTICLES

Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity

JF Ju, D Banerjee, HJ Lenz, KD Danenberg, TC Schmittgen, CP Spears, AH Schonthal, DJ Manno, D Hochhauser, JR Bertino and PV Danenberg
University of Southern California/Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles 90033, USA.

HL-60 cells that stably express transfected wild-type (wt) p53 were used to determine whether restoration of wt p53 increased the chemosensitivity of cells that normally lack p53 activity. The wt p53 HL-60 transfectants (SN3 cells) were more sensitive than the parental (S) cells to a number of common anticancer drugs representing various mechanisms of action, whereas HL-60 cells transfected with p53 genes mutated at codons 248 and 143 were not sensitized. The sensitization ratio due to the transfected wt p53 varied from about 2-fold for cisplatin to over 50-fold for thymidine. Cells treated with the thymidylate synthase inhibitor 5-fluoro-2'-deoxyuridine (FdUrd) were used to study changes in various p53-associated gene expressions. A higher percentage of apoptotic cells among the SN3 cells was observed than among the S cells at each concentration of FdUrd. The S cells had undetectable levels of bax and high levels of bcl-2, whereas the SN3 cells had undetectable levels of bcl-2 levels and appreciable basal levels of bax. After FdUrd treatment of SN3 cells, both p53 and bax levels increased, but the induction of bax was faster than that of p53 and paralleled the appearance of apoptotic DNA laddering. FdUrd treatment induced p21 expression and increased the G1 fraction of the SN3 cells but did not induce p21 or change the phase distribution in the S cells. FdUrd treatment also induced the expression and phosphorylation of cyclin D1 in the SN3 cells but not in the S cells. These results show that transfected wt p53 confers multidrug sensitivity to HL-60 cells by re-adjustment of the expressions of apoptosis genes and displays other properties characteristic of endogenously originated wt p53.


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
A. Catalano, M. Romano, I. Robuffo, L. Strizzi, and A. Procopio
Methionine Aminopeptidase-2 Regulates Human Mesothelioma Cell Survival : Role of Bcl-2 Expression and Telomerase Activity
Am. J. Pathol., August 1, 2001; 159(2): 721 - 731.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
X. Lu, J. Errington, N. J. Curtin, J. Lunec, and D. R. Newell
The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs
Clin. Cancer Res., July 1, 2001; 7(7): 2114 - 2123.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. E. Pestell, S. M. Hobbs, J. C. Titley, L. R. Kelland, and M. I. Walton
Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line
Mol. Pharmacol., March 1, 2000; 57(3): 503 - 511.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.